This Ophthalmic Technology Assessment by the Pediatric Ophthalmology/Strabismus Panel reviewed published literature regarding the efficacy of topical atropine for preventing myopic progression in children. Source: AAO
A suite of formerly untreatable, progressively blinding retinal diseases may now be halted or even reversed, thanks to FDA approval of the gene therapy agent, Luxturna. The announcement marks the first U.S. approval of a gene therapy for an inherited disease. Source: AAO
Stealth BioTherapeutics has gained the fast-track designation for elamipretide, an eye drop aimed at improving mitochondrial function in individuals with Leber’s hereditary optic neuropathy (LHON). Source: AAO
This retrospective study evaluated outcomes of retinoblastoma treated with intravitreal melphalan as salvage for vitreous seeding. Source: AAO
Aerie Pharmaceuticals announced that the FDA has approved their once-daily glaucoma drop, Rhopressa, for lowering IOP in patients with open-angle glaucoma or ocular hypertension. Source: AAO
This week a crescent-shaped burn highlights the need for protective eyewear during solar eclipses, and fungal infections fall prey to a rose-colored eyedrop combined with green fluorescent light. Source: AAO
This cross-sectional study examines the utility of strabismus goggles, which feature a head-fixed laser target display and liquid crystal display shutters, for binocular dissociation. Source: AAO
A recent alteration in the formulation of preservative-free epinephrine could lead to a shortage of mydriatic agents for ophthalmologists, according to an alert issued by the American Society of Cataract and Refractive Surgery (ASCRS). Source: AAO
This is the largest study to examine long-term outcomes following allogenic ocular surface stem cell transplantation for limbal stem cell deficiency. Source: AAO
The FDA has expanded the indication for Omidria, a mydriatic and NSAID combination agent, to include use in pediatric patients from birth through 17 years. Source: AAO